Skip to main content
. 2020 Feb 20;10:3080. doi: 10.1038/s41598-020-58366-z

Figure 1.

Figure 1

Kaplan-Meier plots of the rates of progression-free survival (PFS; 1A) and overall survival (OS; 1B) of cancer patients treated with pazopanib and vorinostat (n = 78) or ixazomib and vorinostat (n = 59).